
Clinical Trials Prevention Project AIDS Clinical Trials Unit First Call NYU The NYU Long-term Nonprogressors Study Oral HPV Study for HIV-Positive Men Primary HIV Infection Study Bellevue Virology Clinic The Men's Sexual Health Project HIV Basics Dictionary Symptoms of HIV Diagnosis of HIV Understanding HIV Test Results Guide to Sexually Transmitted Infections Substance Use and HIV/AIDS HIV Prevention Clinical Trial Basics Treatment Options Women and HIV Immigration and HIV Children and HIV Demographics HIV Lifecycle and Cell-Entry Animations About Us About the AIDS Clinical Trials Unit About the Prevention Project About the NYU School of Medicine CFAR About the Bellevue Virology About the NYU Testing Project News Hablamos Español Opportunities for Giving Privacy and Participation Resources and Links Contact Us Contact Us Map and Directions Make an Appointment Hablamos Español

The Merck 023 / STEP HIV Vaccine Study Update

The following press releases contain important information about the outcome of the study's interim analysis.

December 5, 2007 - Click here to download the joint Merck & Co., Inc. and HIV Vaccine Trials Network (HVTN) Question and Answer document regarding trials using the MRK Ad5 gag/pol/nef vaccine.
November 13, 2007 - Click here to download the joint Merck & Co., Inc. and HIV Vaccine Trials Network (HVTN) press release regarding unblinding of study volunteers.
November 9, 2007 - Click here to visit the HVTN's website to see the presentation of findings from the November 2007 HVTN Conference.
November 7, 2007 - To read the HVTN's press release, "Data from STEP Study Presented at Open Scientific Session Confirm Merck's Investigational HIV Vaccine was not Effective," click here.
October 23, 2007 - Click here to download the Update on the STEP and Phambili HIV Vaccine Trials.
September 21, 2007 - Click here to download the joint Merck & Co., Inc. and HVTN press release about the results of the study's interim analysis.

The NYU Long-term Nonprogressors Study: A collaboration of research programs to learn about the immune systems of HIV-positive people